19 September 2016 - Windtree Therapeutics today announced that the U.S. FDA has granted fast track designation for Aerosurf (lucinactant for inhalation) for the treatment of premature infants with respiratory distress syndrome.

Aerosurf is a novel, investigational combination drug/device product that is being developed to deliver aerosolized KL4 surfactant to premature infants with respiratory distress syndrome, potentially reducing the need for invasive endotracheal intubation and mechanical ventilation to administer surfactant therapy.

Read Windtree Therapeutics press release